CV Sciences GRAS

CV Sciences (OTCQB: CVSI) has announced the financial results of the third quarter, which ended on September 30, 2018. Sales for the quarter increased by 143% to $13.6 million and gross profits increased by 149% to $9.9 million. The company also recorded an adjusted EBITDA of $4.1 million, up from $3.2 million during the same quarter in the previous year. In a statement, CV Sciences CEO Joseph Dowling said that he was encouraged by the company’s strong returns and credits the growth in sales to increased demand for their leading product line, PlusCBD.